

# CGK733

**Catalog No: tcsc1322**



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

905973-89-9

**Formula:**

$C_{23}H_{18}Cl_3FN_4O_3S$

**Pathway:**

Cell Cycle/DNA Damage;PI3K/Akt/mTOR

**Target:**

ATM/ATR;ATM/ATR

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 100$  mg/mL (179.91 mM)

**Observed Molecular Weight:**

555.84

## Product Description


CGK733 is a potent **ATM/ATR** inhibitor, used for the research of cancer.

IC50 & Target: ATM/ATR<sup>[1]</sup>

**In Vitro:** CGK733 (4.2 ng/ $\mu$ L-12.5 ng/ $\mu$ L) enhances taxol-induced cytotoxicity in HBV-positive HCC cells. CGK733 (4.2 ng/ $\mu$ L) accelerates the formation of multinucleated cells and promotes the exit of mitosis in taxol-treated HBV-positive HCC cells<sup>[1]</sup>. CGK733

(10  $\mu$ M) causes the loss of cyclin D1 through the ubiquitin-dependent proteasomal degradation pathway in MCF-7 and T47D breast cancer cell lines. CGK733 (0.6-40  $\mu$ M) shows inhibitory activities against proliferation of LnCap prostate cancer cells, HCT116 colon cancer cells, MCF-7 and T47D estrogen receptor positive breast cancer cells, and MDA-MB436 ER negative breast cancer cells. Moreover, CGK733 inhibits proliferation of non-transformed mouse BALB/c 3T3 embryonic fibroblast cells. In addition, CGK733 (10  $\mu$ M) inhibits MCF-7 proliferation, and the effect can not be suppressed by pan-caspase inhibition<sup>[2]</sup>. CGK733 (10  $\mu$ M) results in 1.6-fold increase in ATM reporter activity in HEK-293 cells<sup>[3]</sup>.

**In Vivo:** CGK733 (25 mg/kg, i.p.) increases the ATM reporter activity (reports inactivation of ATM kinase activity) compared to control mice, with 2.4-fold, 3.1-fold, and 1.3-fold changes at 1, 4, and 8 hours, respectively<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!